vs
Side-by-side financial comparison of JOINT Corp (JYNT) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.
Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $15.2M, roughly 1.4× JOINT Corp). JOINT Corp runs the higher net margin — 6.5% vs -66.3%, a 72.9% gap on every dollar of revenue. On growth, JOINT Corp posted the faster year-over-year revenue change (3.1% vs -8.7%). Over the past eight quarters, Pulmonx Corp's revenue compounded faster (-0.5% CAGR vs -28.6%).
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.
JYNT vs LUNG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $15.2M | $20.6M |
| Net Profit | $991.1K | $-13.7M |
| Gross Margin | 81.4% | 77.9% |
| Operating Margin | 4.9% | -40.9% |
| Net Margin | 6.5% | -66.3% |
| Revenue YoY | 3.1% | -8.7% |
| Net Profit YoY | 5510.5% | 5.5% |
| EPS (diluted) | $0.06 | $-0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $20.6M | ||
| Q4 25 | $15.2M | $22.6M | ||
| Q3 25 | $13.4M | $21.5M | ||
| Q2 25 | $13.3M | $23.9M | ||
| Q1 25 | $13.1M | $22.5M | ||
| Q4 24 | $14.7M | $23.8M | ||
| Q3 24 | $30.2M | $20.4M | ||
| Q2 24 | $30.3M | $20.8M |
| Q1 26 | — | $-13.7M | ||
| Q4 25 | $991.1K | $-10.4M | ||
| Q3 25 | $855.0K | $-14.0M | ||
| Q2 25 | $93.4K | $-15.2M | ||
| Q1 25 | $967.8K | $-14.4M | ||
| Q4 24 | $17.7K | $-13.2M | ||
| Q3 24 | $-3.2M | $-14.1M | ||
| Q2 24 | $-3.6M | $-15.3M |
| Q1 26 | — | 77.9% | ||
| Q4 25 | 81.4% | 77.6% | ||
| Q3 25 | 80.1% | 74.7% | ||
| Q2 25 | 79.1% | 72.1% | ||
| Q1 25 | 77.3% | 72.5% | ||
| Q4 24 | 78.4% | 74.0% | ||
| Q3 24 | 90.7% | 73.7% | ||
| Q2 24 | 90.7% | 73.7% |
| Q1 26 | — | -40.9% | ||
| Q4 25 | 4.9% | -43.8% | ||
| Q3 25 | 1.2% | -66.9% | ||
| Q2 25 | -8.6% | -62.0% | ||
| Q1 25 | -5.2% | -64.6% | ||
| Q4 24 | 5.5% | -56.5% | ||
| Q3 24 | -1.6% | -69.3% | ||
| Q2 24 | -5.9% | -75.2% |
| Q1 26 | — | -66.3% | ||
| Q4 25 | 6.5% | -46.1% | ||
| Q3 25 | 6.4% | -64.9% | ||
| Q2 25 | 0.7% | -63.6% | ||
| Q1 25 | 7.4% | -64.1% | ||
| Q4 24 | 0.1% | -55.4% | ||
| Q3 24 | -10.5% | -69.4% | ||
| Q2 24 | -11.9% | -73.7% |
| Q1 26 | — | $-0.33 | ||
| Q4 25 | $0.06 | $-0.25 | ||
| Q3 25 | $0.06 | $-0.34 | ||
| Q2 25 | $0.01 | $-0.38 | ||
| Q1 25 | $0.06 | $-0.36 | ||
| Q4 24 | $0.01 | $-0.33 | ||
| Q3 24 | $-0.21 | $-0.36 | ||
| Q2 24 | $-0.24 | $-0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.6M | $61.6M |
| Total DebtLower is stronger | — | $37.3M |
| Stockholders' EquityBook value | $15.1M | $45.8M |
| Total Assets | $61.0M | $120.0M |
| Debt / EquityLower = less leverage | — | 0.82× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $61.6M | ||
| Q4 25 | $23.6M | $69.8M | ||
| Q3 25 | $29.7M | $76.5M | ||
| Q2 25 | $29.8M | $75.5M | ||
| Q1 25 | $21.9M | $74.6M | ||
| Q4 24 | $25.1M | $70.9M | ||
| Q3 24 | $20.7M | $63.3M | ||
| Q2 24 | $17.5M | $63.5M |
| Q1 26 | — | $37.3M | ||
| Q4 25 | — | $37.1M | ||
| Q3 25 | — | $37.1M | ||
| Q2 25 | — | $37.1M | ||
| Q1 25 | — | $37.2M | ||
| Q4 24 | — | $37.2M | ||
| Q3 24 | — | $37.2M | ||
| Q2 24 | — | $37.2M |
| Q1 26 | — | $45.8M | ||
| Q4 25 | $15.1M | $54.1M | ||
| Q3 25 | $22.7M | $60.0M | ||
| Q2 25 | $23.2M | $69.1M | ||
| Q1 25 | $22.8M | $77.7M | ||
| Q4 24 | $20.7M | $85.8M | ||
| Q3 24 | $20.5M | $93.9M | ||
| Q2 24 | $23.2M | $101.2M |
| Q1 26 | — | $120.0M | ||
| Q4 25 | $61.0M | $129.3M | ||
| Q3 25 | $69.4M | $138.3M | ||
| Q2 25 | $73.2M | $147.2M | ||
| Q1 25 | $80.1M | $150.7M | ||
| Q4 24 | $83.2M | $162.8M | ||
| Q3 24 | $79.6M | $167.4M | ||
| Q2 24 | $82.4M | $172.6M |
| Q1 26 | — | 0.82× | ||
| Q4 25 | — | 0.69× | ||
| Q3 25 | — | 0.62× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.37× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | — |
| Free Cash FlowOCF − Capex | $334.7K | — |
| FCF MarginFCF / Revenue | 2.2% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | 1.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.8M | $-7.1M | ||
| Q3 25 | $1.8M | $-8.2M | ||
| Q2 25 | $868.6K | $-3.9M | ||
| Q1 25 | $-3.7M | $-13.2M | ||
| Q4 24 | $9.4M | $-6.7M | ||
| Q3 24 | $3.4M | $-7.2M | ||
| Q2 24 | $-973.5K | $-5.8M |
| Q1 26 | — | — | ||
| Q4 25 | $334.7K | $-7.1M | ||
| Q3 25 | $1.5M | $-8.3M | ||
| Q2 25 | $363.6K | $-4.0M | ||
| Q1 25 | $-4.0M | $-13.5M | ||
| Q4 24 | $8.2M | $-6.8M | ||
| Q3 24 | $3.2M | $-7.7M | ||
| Q2 24 | $-1.2M | $-6.2M |
| Q1 26 | — | — | ||
| Q4 25 | 2.2% | -31.4% | ||
| Q3 25 | 10.9% | -38.4% | ||
| Q2 25 | 2.7% | -16.6% | ||
| Q1 25 | -30.8% | -60.0% | ||
| Q4 24 | 55.9% | -28.8% | ||
| Q3 24 | 10.6% | -37.6% | ||
| Q2 24 | -4.1% | -30.0% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 0.1% | ||
| Q3 25 | 2.4% | 0.4% | ||
| Q2 25 | 3.8% | 0.2% | ||
| Q1 25 | 2.5% | 1.3% | ||
| Q4 24 | 8.1% | 0.5% | ||
| Q3 24 | 0.8% | 2.0% | ||
| Q2 24 | 0.9% | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.86× | — | ||
| Q3 25 | 2.07× | — | ||
| Q2 25 | 9.30× | — | ||
| Q1 25 | -3.82× | — | ||
| Q4 24 | 532.98× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
LUNG
Segment breakdown not available.
